Tweet
Bone Marrow Transplant. Author manuscript; available in PMC 2013 January 1.
Published in final edited form as:
Bone Marrow Transplant. 2012 July; 47(7): 946–951.
Published online 2011 November 7. doi: 10.1038/bmt.2011.208
PMCID: PMC3276694
NIHMSID: NIHMS326930
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results
James D. Bowen, MD,1 George H. Kraft, MD, MS,2 Annette Wundes, MD,3 QingYan Guan, MS,4 Kenneth R. Maravilla, MD,4 Theodore A. Gooley, PhD,5,6 Peter A. McSweeney, MD,7 Steven Z. Pavletic, MD,8 Harry Openshaw, MD,9 Rainer Storb, MD,5,6 Mark Wener, MD,2 Bernadette A. McLaughlin, RN,6 Gretchen R. Henstorf, CCRC,6 and Richard A. Nash, MD5,6
Abstract.
The purpose of the study was to determine the long-term safety and effectiveness of high-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT) in advanced multiple sclerosis (MS). Total body irradiation, cyclophosphamide, and antithymocyte globulin were followed by transplantation of autologous, CD34-selected peripheral blood stem cells (PBSC). Neurological examinations, brain MRIs and cerebrospinal fluid (CSF) for oligoclonal bands (OCB) were serially evaluated. Patients (n=26, mean EDSS=7.0, 17 secondary progressive, 8 primary progressive, 1 relapsing/remitting) were followed for a median of 48 months after HDIT followed by AHCT. The 72-month probability of worsening ≥ 1.0 EDSS point was 0.52 (95% CI, 0.30 to 0.75). Five patients had an EDSS at baseline of ≤ 6.0; four of these had not failed treatment at last study visit. OCB in CSF persisted with minor changes in the banding pattern. Four new or enhancing lesions were seen on MRI, all within 13 months of treatment. In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable as long as 7 years after transplant. Non-inflammatory events may have contributed to neurological worsening after treatment. HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.
Full Study:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276694/
Published in final edited form as:
Bone Marrow Transplant. 2012 July; 47(7): 946–951.
Published online 2011 November 7. doi: 10.1038/bmt.2011.208
PMCID: PMC3276694
NIHMSID: NIHMS326930
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results
James D. Bowen, MD,1 George H. Kraft, MD, MS,2 Annette Wundes, MD,3 QingYan Guan, MS,4 Kenneth R. Maravilla, MD,4 Theodore A. Gooley, PhD,5,6 Peter A. McSweeney, MD,7 Steven Z. Pavletic, MD,8 Harry Openshaw, MD,9 Rainer Storb, MD,5,6 Mark Wener, MD,2 Bernadette A. McLaughlin, RN,6 Gretchen R. Henstorf, CCRC,6 and Richard A. Nash, MD5,6
Abstract.
The purpose of the study was to determine the long-term safety and effectiveness of high-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT) in advanced multiple sclerosis (MS). Total body irradiation, cyclophosphamide, and antithymocyte globulin were followed by transplantation of autologous, CD34-selected peripheral blood stem cells (PBSC). Neurological examinations, brain MRIs and cerebrospinal fluid (CSF) for oligoclonal bands (OCB) were serially evaluated. Patients (n=26, mean EDSS=7.0, 17 secondary progressive, 8 primary progressive, 1 relapsing/remitting) were followed for a median of 48 months after HDIT followed by AHCT. The 72-month probability of worsening ≥ 1.0 EDSS point was 0.52 (95% CI, 0.30 to 0.75). Five patients had an EDSS at baseline of ≤ 6.0; four of these had not failed treatment at last study visit. OCB in CSF persisted with minor changes in the banding pattern. Four new or enhancing lesions were seen on MRI, all within 13 months of treatment. In this population with high baseline EDSS, a significant proportion of patients with advanced MS remained stable as long as 7 years after transplant. Non-inflammatory events may have contributed to neurological worsening after treatment. HDIT/AHCT may be more effective in patients with less advanced relapsing/remitting MS.
Full Study:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276694/